Former EVP, Chief Financial Officer · REGENXBIO Inc. (RGNX)

Vit Vasista

A named executive officer of REGENXBIO in every fiscal year CompBrief holds from FY2019 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,226,951

Salary $357,705Stock awards $293,917

FY2023: $2,618,404

7th of 7 named executive officers at Regenxbio by FY2024 total.

7 named officers on file for REGENXBIO, FY2024

Vit Vasista’s pay file — $29

  • 6 fiscal years of pay, line by line
  • 9 equity grants, each cited to its filing
  • RGNX’s disclosed peer group of 15 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how REGENXBIO’s whole pay program stands against its peers

  • REGENXBIO’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RGNX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 8, 2025 (DEF 14A).

Free

Get Vit Vasista’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Vit Vasista compensation by year

REGENXBIO Summary Compensation Table · all 6 fiscal years held
In US dollars, as REGENXBIO reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023FY2024
Salary$439,988$453,188$466,783$480,787$500,018$357,705
Bonus$0$0$525,000$0$0$0
Stock awards$0$0$557,628$305,359$1,027,372$293,917
Option awards$1,548,133$1,230,788$1,535,018$875,493$924,535$872,398
Non-equity incentive$180,395$181,275$245,061$173,083$147,505$150,005
Pension and deferred compensation$0$0$0$0$0$0
All other$16,100$16,388$16,675$17,538$18,975$552,926
Total$2,184,616$1,881,639$3,346,165$1,852,260$2,618,404$2,226,951

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: REGENXBIO Inc. DEF 14A filed April 8, 2025, accession 0000950170-25-052069, and prior-year filings. Open the filing on EDGAR.

How this page was built: the REGENXBIO Inc. filed document, accession 0000950170-25-052069. Every figure is read from that document and cited to the page and table it appears in. Filed April 8, 2025.

$2.2M
$1.9M
$3.3M
$1.9M
$2.6M
$2.2M
FY19
FY20
FY21
FY22
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU34,630$267,690—
RSU16,026$123,881—
RSU4,450$34,399—
RSU3,100$23,963—
Option76,313—$18.34
Option1,171—$44.97
Option11,510—$34.31
Option34,496—$22.25

Per the Outstanding Equity Awards at Fiscal Year-End table in REGENXBIO Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

REGENXBIO’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Kenneth MillsFormer President and CEO$5,507,038
Curran SimpsonPresident and Chief Executive Officer$4,784,543
Mitchell ChanEVP, Chief Financial Officer$3,205,294
Olivier DanosEVP, Chief Scientific Officer$2,956,949
Patrick ChristmasEVP, Chief Strategy and Legal Officer$2,737,813
Stephen PakolaEVP, Chief Medical Officer$2,696,858
Vit Vasista · this pageFormer EVP, Chief Financial Officer$2,226,951

The full REGENXBIO compensation record

free company brief

This page is one person within REGENXBIO's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are REGENXBIO's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Vit Vasista's compensation dossier · One-time report. No refunds.